Company Analysis
Sign in

TransCode Therapeutics, Inc. (RNAZ)

Nasdaq: RNAZ · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2020
Full chart Alerts Compare
Grade2.9
◀ Past 2.4● Present 1.7▶ Future 4.3
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedApr 15, 2026Apr 15, 2025Apr 1, 2024Mar 31, 2023Mar 31, 2022·
Research and development13,421,8489,706,35812,263,53010,232,3662,753,966284,459
General and administrative5,771,0635,954,3397,154,9868,401,462r3,397,169442,145
Total operating expenses27,980,07115,660,69719,418,51618,633,828r6,151,135726,604
Operating income-27,980,071-15,660,697-19,418,516-18,633,828r-6,151,135-726,604
Interest expense6,61626,81355,89931,98695,070394,573
Interest and investment income79,1986845,28520,410664136
Total non-operating income (expense)-6,454,937-1,094,274872,4211,068,860r-692,264-1,617,289
Income before income taxes-34,435,008-16,754,971····
Income tax expense226,06900053,0510
Net income including non-controlling interests-34,661,076-16,754,971-18,546,095-17,564,968-6,843,399-2,343,893
Net income-34,661,076-16,754,971-18,546,095-17,564,968-6,843,399-2,343,893
Net income to common shareholders-36,271,287-16,785,572-18,546,095···
Earnings per share, basic-52.59-1,336.63r-96,965.6835rb-1,013,388.2587rb-606,466.2507b-381,849.1208b
Earnings per share, diluted-52.59-1,336.63r-96,965.6835rb-1,013,388.2587rb-606,466.2507b-381,849.1208b
Weighted average shares, basic689,71312,558r191rb17rb11b6b
Weighted average shares, diluted689,71312,558r191rb17rb11b6b
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the change of share basis.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton RNAZ · research, not advice